Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESSO 45 | Can surgery be omitted in exceptional responders with HER2+ and TNBC?

Han-Byoel Lee, MD, PhD, Seoul National University Hospital, Seoul, South Korea, discusses emerging evidence for omitting breast and axillary surgery in exceptional responders to neoadjuvant systemic therapy for HER2-positive and triple-negative breast cancers. Upcoming data from the JCOG1806 (jRCTs031190129) and OPTIMIST (NCT05505357) trials will collectively provide evidence on the oncologic safety of surgery omission in carefully selected patients. The ASLAN (NCT04993625) trial also examined axillary surgery omission and demonstrated promising interim results. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

So this is an involving field with not that much data to support the admission of surgery for the breast and also axilla. However, we do have the preliminary results from the MD Anderson trial, which looked at omitting breast surgery for exceptional responders after neurodegenerative systemic therapy for triple negative and HER2 POSITIVE breast cancers. They enrolled 50 patients, of which 31, they enrolled 50, patients and all of them went, received vacuum-assisted biopsy, at least 12 cores using a 9-gauge needle, which showed in 31 patients there was no residual tumor...

So this is an involving field with not that much data to support the admission of surgery for the breast and also axilla. However, we do have the preliminary results from the MD Anderson trial, which looked at omitting breast surgery for exceptional responders after neurodegenerative systemic therapy for triple negative and HER2 POSITIVE breast cancers. They enrolled 50 patients, of which 31, they enrolled 50, patients and all of them went, received vacuum-assisted biopsy, at least 12 cores using a 9-gauge needle, which showed in 31 patients there was no residual tumor. And in those patients, they were omitted breast surgery. In patients who had a clinical node POSITIVE disease, they also had symptom of the biopasy, which were confirmed to have no residual tumors. There was no residual lymph node disease. In those patients, they reported a five-year disease-free survival, ipsilateral breast tumor recurrence-free survival of 100%, and there were no deaths or no disease – free survivor events also, which was reported, published last year in Drama Oncology. Now they have, they’re following up, they have more than 60 months of medium follow-up, which still shows no recurrence. So this is, this really showed for exceptional responders to neurodegenerative systemic therapy with careful patient selection and the very strict biopsy requirements, we can omit surgery, safely omit surgery in those patients. That’s actually the only data we have currently. However, we are looking forward to the Japanese JCOG 1806 trial, which will be presented as oral presentation, in the general session of the San Antonio Breast Cancer Symposium this year. They enrolled clinically T1 to 2, N0 HER2-POSITIVE breast cancer who received neoadjuvant systemic therapy, and they received, in a lot of the patients, most of the patients did receive a breast biopsy, needle biopasy. It wasn’t necessarily vacuum-assisted. A lot of those patients were coronary biopsies, and in those patients who had no, no suspicious findings on ultrasound, they did not go, even receive any biopsy. And a lot of those patients, I think about 150, more than 150 patients, did not receive surgery for the breast, and because it’s going to be announced in San Antonio, I talked to the author, they said the results were promising. So, and I can say that, I shouldn’t speculate or anything, but the same group is, has already started another trial for T1-negative breast cancer. They started enrolling in September this year with a similar scheme. So, and also, they’re also planning a second JCOG-1806 trial for N0-positives as well. So, I think this is, going forward, we will get more data on the oncologic safety of omitting surgery for, for good responders, exceptional responders, to chemotherapy, systemic therapy, especially in the HER2-POSITIVE and triple-negative breast cancer. Especially the JCOG-1806 trial, and some of the other trials ongoing in Italy and in China, their inclusion criteria is very early. Even if their biology is aggressive in triple – negative and HER2 positives, their clinical presentation is pretty early. But I am leading a trial in South Korea called the OPTIMUS trial, which includes a broader, broader, broader spectrum of patients. So, we are including HER2-POSITIVE breast cancer, triple-negative breast cancer and low ER cancers with clinical stage 2 to 3 disease. A lot of our patients are, includes clinical N2 patients as well. So, we do, we select our patients according to MRI, size and lesion to background similar enhancement ratio, and do a vacuum-assisted biopsy using 7 to 10 gauge needles. And we get at least 6 cores, instead of the 12 cores required for the MD Anderson trial. We are at about 50 .6 % accrual right now. We expect to finish the accruals by 2028. And we’ll see, currently we are going through DSMB to monitor the safety. I think there’s going to be no problem with the safety, and we will be able to continue with the study. It will be the largest cohort. We are enrolling 447 patients in total. So, later on, if we can put together all the data from the Anderson trial, the Japanese trials, our trial, The OPTIMUS trial and some other trials, I think we are headed in a direction where we can say that we can safely omit surgery for the breast. In terms of surgery for The Axilla, there are several trials that are ongoing, namely The Aslan trial from Korea and the EU Breast 01 trial from Europe. Both trials finished accrual, and The Asalan trial actually presented the pre-planned, pre-specified trials for three-year interim analysis at the GBCC meeting this year in April in Korea. The Aslan trial performed surgery for the breast in patients with exceptional response for HER2-POSITIVE triple-negative breast cancer with clinical T1-3 and N0-1 disease. After a breast-conserving surgery, if the surgery confirms a PCR in the breast, the patients were omitted until after biopsy. We analyzed 180 patients that were enrolled and went through per-protocol analysis, which showed only two recurrence-free survival events. So a three-year interim analysis with the patient’s median follow-up was about 32 months. Only two recurrences, one brain metastasis and one ipsilateral breast tumor recurrence, and no axillary recurrences. So the results were promising. We will report the full five-year analysis later on, but I think we can say that with a breast PCR and very low clinical end-staging before neoadjuvant system therapy, we might be able to safely omit symptoms of biopsy. There’s one more study I would like to mention, namely the NEO-Nautilus trial. It’s the neoadjuvant version of the Nautilus trial, which omits sentinel lymphoid biopsy in the upfront surgery setting. NEO-Nautilis omits sentinel-lymphoid biopsies after neoadjunct system therapy. It enrolls all subtypes. So for all subtype, it has to be clinically N0. For clinically N1 tumor, it has be either HER2 POSITIVE or triple-negative breast cancer with a response of more than 30 % on MRI. So that trial is at about 35 % accrual. So hopefully we can accrue the full number is over 400. I don’t remember the exact numbers, but hopefully we can accrued the patients quickly and show that we can really omit surgery for the axilla in these patients after neoadjuvant system therapy.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.